Skip to main content
Log in

Case study on drug-related adverse effects of hepatitis C therapy

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

The case of a 46-year-old woman with chronic hepatitis C who was prescribed subcutaneous pegylated interferon once a week and oral ribavirin once a day is presented. Within 24 h after the first injection to her left arm, the patient developed pruritus and erythematous papules at the injection site and painful papules on her hands. After immediate administration of antihistamines, the pruritus and papules remitted. One wk later, after injection in the right arm, skin lesions and pruritus were seen. After the third injection to the abdomen, the patient developed a rash, and after the fourth and fifth injections to other areas of the abdomen, injection-site papules were seen. The patient had no skin reactions for the next 12 mo, with the exception of injection-site papules. Hepatitis C virus RNA was negative after 12 mo of treatment. Clearly, patience is important during hepatitis C therapy in order to avoid unnecessary examinations and to promote successful outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Willems M, Munte K, Vrolijk JM, et al. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection.Br J Dermatol. 2003; 149: 390–394.

    Article  PubMed  CAS  Google Scholar 

  2. Gurguta C, Kauer C, Bergholz U, Formann E, Steindl-Munda P, Ferenci P. Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C.Am J Gastroenterol. 2006; 101: 197–198.

    Article  PubMed  Google Scholar 

  3. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: hepatitis interventional therapy group.N Engl J Med. 1998; 339: 1485–1492.

    Article  PubMed  CAS  Google Scholar 

  4. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Health Technol Assess. 2004; 8:iii-iv, 1–125.

    Google Scholar 

  5. Abe S, Narita R, Oto T, Tabaru A, Otsuki M. Effect of combination therapy with ribavirin and high-dose interferon-α2b for 24 weeks in chronic hepatitis C.J Gastroenterol Hepatol. 2006; 21: 308–312.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basaranoglu, M., Celebi, S., Karaaslan, H. et al. Case study on drug-related adverse effects of hepatitis C therapy. Adv Therapy 23, 769–771 (2006). https://doi.org/10.1007/BF02850316

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850316

Keywords

Navigation